BE2018C045I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2018C045I2 BE2018C045I2 BE2018C045C BE2018C045C BE2018C045I2 BE 2018C045 I2 BE2018C045 I2 BE 2018C045I2 BE 2018C045 C BE2018C045 C BE 2018C045C BE 2018C045 C BE2018C045 C BE 2018C045C BE 2018C045 I2 BE2018C045 I2 BE 2018C045I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56521004P | 2004-04-22 | 2004-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2018C045I2 true BE2018C045I2 (en, 2012) | 2024-08-08 |
Family
ID=35196733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2018C045C BE2018C045I2 (en, 2012) | 2004-04-22 | 2018-11-30 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8022279B2 (en, 2012) |
| EP (2) | EP2407169A1 (en, 2012) |
| JP (1) | JP4972545B2 (en, 2012) |
| AU (1) | AU2005235455B2 (en, 2012) |
| BE (1) | BE2018C045I2 (en, 2012) |
| CA (1) | CA2564542C (en, 2012) |
| CY (2) | CY1113012T1 (en, 2012) |
| ES (1) | ES2388064T3 (en, 2012) |
| FR (1) | FR18C1047I2 (en, 2012) |
| IL (1) | IL178779A (en, 2012) |
| NL (1) | NL300960I2 (en, 2012) |
| PT (1) | PT1744764E (en, 2012) |
| WO (1) | WO2005102359A1 (en, 2012) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006032136A1 (en) * | 2004-09-20 | 2006-03-30 | British Columbia Cancer Agency Branch | Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin |
| US9943481B2 (en) * | 2005-05-26 | 2018-04-17 | Biorest Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
| JP5314600B2 (ja) * | 2007-02-16 | 2013-10-16 | セラター・ファーマスーティカルズ・インコーポレーテッド | 造血器癌および増殖性疾患の治療のための固定した薬物比 |
| EP2257310A2 (en) * | 2008-02-26 | 2010-12-08 | Nerviano Medical Sciences S.r.l. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
| CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
| CN108853031A (zh) * | 2011-10-21 | 2018-11-23 | 切拉托尔制药公司 | 冻干脂质体 |
| CN108686203A (zh) | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| BR112014028094B1 (pt) | 2012-05-09 | 2022-03-03 | Cantex Pharmaceuticals, Inc | Uso de um heparinoide interagindo com fator de plaqueta 4 |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| ES2826896T3 (es) | 2015-05-04 | 2021-05-19 | Versantis AG | Método para preparar vesículas con gradiente de pH transmembrana |
| JP6564873B2 (ja) * | 2015-11-02 | 2019-08-21 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
| WO2017083592A1 (en) | 2015-11-11 | 2017-05-18 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| KR20200027548A (ko) * | 2017-07-09 | 2020-03-12 | 바이오사이트 리미티드 | 병용 암 요법 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| MX2021003527A (es) | 2018-09-25 | 2021-05-27 | Celator Pharmaceuticals Inc | Tratamiento de baja intensidad de trastornos hematologicos. |
| JP7553453B2 (ja) | 2019-03-01 | 2024-09-18 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| CN113181117B (zh) * | 2021-03-22 | 2022-08-26 | 沈阳药科大学 | 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2025088367A1 (en) * | 2023-10-27 | 2025-05-01 | Jodas Expoim Pvt. Ltd | Liposomal composition of idarubicin and cytarabine and process for preparation thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (en, 2012) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5059421A (en) * | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| ES2186484B1 (es) | 2000-10-10 | 2004-07-01 | Lipotec, S.A. | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| IL161187A0 (en) * | 2001-10-03 | 2004-08-31 | Celator Technologies Inc | Liposome compositions containing metal ions and therapeutic agents |
| EP1608337A2 (en) * | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Combination compositions of camptothecins and fluoropyrimidines |
| WO2005000266A2 (en) * | 2003-05-22 | 2005-01-06 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
-
2005
- 2005-04-22 ES ES05738885T patent/ES2388064T3/es not_active Expired - Lifetime
- 2005-04-22 PT PT05738885T patent/PT1744764E/pt unknown
- 2005-04-22 EP EP11185094A patent/EP2407169A1/en not_active Withdrawn
- 2005-04-22 WO PCT/CA2005/000625 patent/WO2005102359A1/en active Application Filing
- 2005-04-22 CA CA2564542A patent/CA2564542C/en not_active Expired - Lifetime
- 2005-04-22 EP EP05738885A patent/EP1744764B1/en not_active Expired - Lifetime
- 2005-04-22 JP JP2007508701A patent/JP4972545B2/ja not_active Expired - Lifetime
- 2005-04-22 AU AU2005235455A patent/AU2005235455B2/en active Active
- 2005-04-22 US US11/587,112 patent/US8022279B2/en active Active
-
2006
- 2006-10-22 IL IL178779A patent/IL178779A/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,807 patent/US8431806B2/en not_active Expired - Lifetime
-
2012
- 2012-07-10 CY CY20121100616T patent/CY1113012T1/el unknown
-
2018
- 2018-11-14 FR FR18C1047C patent/FR18C1047I2/fr active Active
- 2018-11-30 BE BE2018C045C patent/BE2018C045I2/nl unknown
- 2018-12-07 CY CY2018033C patent/CY2018033I1/el unknown
- 2018-12-11 NL NL300960C patent/NL300960I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2564542A1 (en) | 2005-11-03 |
| WO2005102359A8 (en) | 2005-12-15 |
| FR18C1047I1 (fr) | 2019-03-22 |
| US20120009252A1 (en) | 2012-01-12 |
| AU2005235455A1 (en) | 2005-11-03 |
| HK1097194A1 (en) | 2007-06-22 |
| IL178779A0 (en) | 2007-05-15 |
| US8022279B2 (en) | 2011-09-20 |
| FR18C1047I2 (fr) | 2019-10-04 |
| CY2018033I2 (el) | 2019-07-10 |
| US20070286897A1 (en) | 2007-12-13 |
| ES2388064T3 (es) | 2012-10-08 |
| US8431806B2 (en) | 2013-04-30 |
| NL300960I2 (nl) | 2019-05-22 |
| WO2005102359A1 (en) | 2005-11-03 |
| JP2007533670A (ja) | 2007-11-22 |
| EP1744764B1 (en) | 2012-05-30 |
| CY1113012T1 (el) | 2016-04-13 |
| CA2564542C (en) | 2012-11-27 |
| IL178779A (en) | 2013-12-31 |
| CY2018033I1 (el) | 2019-07-10 |
| JP4972545B2 (ja) | 2012-07-11 |
| AU2005235455B2 (en) | 2011-01-20 |
| EP2407169A1 (en) | 2012-01-18 |
| EP1744764A4 (en) | 2009-04-01 |
| PT1744764E (pt) | 2012-08-30 |
| EP1744764A1 (en) | 2007-01-24 |